Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.09+0.13 (+2.62%)
At close: 04:00PM EST
5.25 +0.16 (+3.14%)
After hours: 06:12PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.96
Open5.05
Bid5.05 x 3200
Ask5.13 x 900
Day's Range5.01 - 5.25
52 Week Range2.09 - 18.50
Volume264,066
Avg. Volume246,837
Market Cap72.239M
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for UBX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Unity Biotechnology, Inc.
    Analyst Report: Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    UNITY Biotechnology Reports Granting of New Employment Inducement Award

    SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from January 3, 2023, through January 17, 2023, the Compensation Committee of the Board of Directors (the “Board”) granted a new employee a stock-based award covering an aggregate of 900 shares of UNITY common stock, including options to purchase an aggregate of 900 share

  • Insider Monkey

    10 Penny Stocks That Will Make You A Millionaire

    In this article, we will discuss the 10 penny stocks that will make you a millionaire. If you want to explore similar stocks, you can also take a look at 5 Penny Stocks That Will Make You A Millionaire. Penny stocks can be an attractive option for investors looking to get in on the stock […]

  • GlobeNewswire

    UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates

    - Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION Study in wet Age-Related Macular Degeneration Expected in First Quarter of 2023 - - As of September 30, 2022, UNITY had approximately $103.9 million in cash, cash equivalents and marketable securities, prov

Advertisement
Advertisement